These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29467200)

  • 1. Effectiveness
    Woodcock A; Boucot I; Leather DA; Crawford J; Collier S; Bakerly ND; Hilton E; Vestbo J
    Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29467200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Data and Randomised Controlled Trials: The Salford Lung Study.
    Leather DA; Jones R; Woodcock A; Vestbo J; Jacques L; Thomas M
    Adv Ther; 2020 Mar; 37(3):977-997. PubMed ID: 31927698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
    Oba Y; Chandran AV; Devasahayam JV
    COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large trials, new knowledge: the changing face of COPD management.
    De Soyza A; Calverley PM
    Eur Respir J; 2015 Jun; 45(6):1692-703. PubMed ID: 25792640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results.
    Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I
    BMJ Open; 2018 Mar; 8(3):e019475. PubMed ID: 29581202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.
    Albertson TE; Murin S; Sutter ME; Chenoweth JA
    Pragmat Obs Res; 2017; 8():175-181. PubMed ID: 29033625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Guirguis-Blake JM; Senger CA; Webber EM; Mularski RA; Whitlock EP
    JAMA; 2016 Apr; 315(13):1378-93. PubMed ID: 27046366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
    Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
    Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?
    Scichilone N; Basile M; Battaglia S; Bellia V
    Respiration; 2014; 87(1):11-7. PubMed ID: 24281343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care.
    Thomas M; Radwan A; Stonham C; Marshall S
    COPD; 2014 Jun; 11(3):300-9. PubMed ID: 24152210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L; Cates CJ; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.
    Tricco AC; Strifler L; Veroniki AA; Yazdi F; Khan PA; Scott A; Ng C; Antony J; Mrklas K; D'Souza J; Cardoso R; Straus SE
    BMJ Open; 2015 Oct; 5(10):e009183. PubMed ID: 26503392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of overlapping asthma-chronic obstructive pulmonary disease: Can guidelines contribute in an evidence-free zone?
    Reddel HK
    J Allergy Clin Immunol; 2015 Sep; 136(3):546-52. PubMed ID: 26343938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.
    Dal-Ré R
    J Eval Clin Pract; 2018 Feb; 24(1):258-261. PubMed ID: 28685913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trial Risk in Chronic Obstructive Pulmonary Disease: The Effects of Drug Class and Inclusion Criteria.
    Tam JT; Parker JL; Anastasopulos D; Balter MS
    Respiration; 2016; 91(1):79-86. PubMed ID: 26695682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obtaining real-world evidence: the Salford Lung Study.
    New JP; Bakerly ND; Leather D; Woodcock A
    Thorax; 2014 Dec; 69(12):1152-4. PubMed ID: 24603195
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.